Abstract 1670
Background
International recommendations for cancer control support the organization of breast cancer care with a multidisciplinary approach in Breast Units (BU). The BU of the Catalan Institute of Oncology (ICO) is a functional unit for breast cancer with oncologists, gynecologists, surgeons and cancer nurses specialized in for diagnosis, treatment and monitoring breast cancer patients. Pathologists and radiologists are also working with the BU. Several international guidelines include nurse as essential part of BU and defined their model of care, management and functions.
The objective is to describe care nurse model and activity of the Breast Unit in a cancer center.
Methods
Retrospective cross-sectional study. Population cancer patients attended at the BU of the ICO during 2016 to 2017 were included. Variables collected were socio-demographic, clinical - pathology and treatment and nursing interventions for patients. Data was extracted from the clinical record. Data analysis was descriptive using the statistical package SPSS v15.
Results
Total of 382 patients. Nursing interventions in patients with early stage breast cancer were: 321 (98.85%) visits before the start of treatments; 322 (99.1%) visits during treatments; 230 (70.8%) visits after finishing treatments; 319 (98.2%) coordination activities for the continuity of care and 136 (14.8%) consultations and derivations to professionals of other services.
Nursing interventions in patients with advanced stage breast cancer: 32 (56.1%) visits before the start of treatments; 33 (57.9%) visits during treatments; 17 (29.8%) coordination activities for the continuity of care; and 12 (21.8%) consultations and derivations to professionals of other services.
Conclusions
According to this multidisciplinary model of care, patients with breast cancer in the early stages have a high level of clinical contacts with the nurse along the cancer care process. However, there is a high percentage of patients with advanced disease that could not benefit from an early and continued access to nurse.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Generalitat of Catalonia, Department of Health.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5760 - Landscape of PD-L1 expression status in Chinese solid tumor patients.
Presenter: Yi Zhong
Session: Poster Display session 3
Resources:
Abstract
3733 - Anti-cancer and immunomodulatory effects of cobimetinib in triple negative breast cancer
Presenter: Chun-Yu Liu
Session: Poster Display session 3
Resources:
Abstract
4426 - Differential expression of immunoregulatory molecules and highly-associated cancer genes may provide novel insights into strategic trial design for therapeutics
Presenter: Jacob Adashek
Session: Poster Display session 3
Resources:
Abstract
2752 - Insights into the Tumor Immune Microenvironment using Tissue Phenomics to Drive Cancer Immunotherapy
Presenter: Martin Groher
Session: Poster Display session 3
Resources:
Abstract
5713 - Immune competent somatic mosaic model of colorectal cancer
Presenter: Stefania Napolitano
Session: Poster Display session 3
Resources:
Abstract
1898 - Genomic correlates of response to anti-PDL1 Atezolizumab in non-small-cell lung cancer OAK and POPLAR trials
Presenter: Hari Singhal
Session: Poster Display session 3
Resources:
Abstract
3246 - Erdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
3311 - High level of activity of Nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program
Presenter: Christophe Tournigand
Session: Poster Display session 3
Resources:
Abstract
2314 - TP53 and ATM Co-mutation Predicts Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Presenter: Yu Chen
Session: Poster Display session 3
Resources:
Abstract
4692 - Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
Presenter: Raquel Laza-Briviesca
Session: Poster Display session 3
Resources:
Abstract